ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: FR-OR025

Defining Kidney Dysfunction in the Community Setting: The ISN 0by25 Initiative

Session Information

Category: Acute Kidney Injury

  • 101 AKI: Epidemiology, Risk Factors, and Prevention

Authors

  • Macedo, Etienne, University of California San Diego Medical Center, La Jolla, California, United States
  • Sharma, Sanjib Kumar, B.P.Koirala Institute of Health Sciences, Dharan, Nepal
  • Hemmila, Ulla, College of Medicine, Malawi, Kokemäki, Finland
  • Claure-Del Granado, Rolando, Hospital Obrero #2 Universidad Mayor de San Simon, Zona Sarco, Bolivia, Plurinational State of
  • Shah, Bhupendra, B.P.Koirala Institute of Health Sciences, Dharan, Nepal
  • Mzinganjira, Henry E., MOH , Blantyre, Malawi
  • Cerda, Jorge, Capital District Renal Physicians, Albany, New York, United States
  • Burdmann, Emmanuel A., University of Sao Paulo Medical School, Sao Paulo, Brazil
  • Rocco, Michael V., Wake Forest School of Medicine, Winston-Salem, North Carolina, United States
  • Mehta, Ravindra L., University of California San Diego Medical Center, La Jolla, California, United States

Group or Team Name

  • ISN 0by25
Background

Community-acquired acute kidney injury (AKI) is common, but often unrecognized in resource-constrained settings. Limited lab assessments and unavailable informationon the prior state of kidney health contribute to this lack of recognition. In this study, we evaluated the efficacy of point of care (POC) serum creatinine (sCr) and urine dipstick tests to identify patients with kidney dysfunction at presentation to community health centres (CHC) and emergency departments (ED), as part of the International Society of Nephrology (ISN) 0by25 Pilot Feasibility Project.

Methods

Patients (pts) presenting at CHC or ED with signs or symptoms associated with high/moderate risk of developing AKI underwent sCr POC test and urine dipstick. At enrollment, pts were classified as chronic kidney disease (CKD) based on prior history, proteinuria(>1+) and/or baseline sCr within 12 mos by estimated GFR (CKD-EPI equation)) <60 mL/min/1.73 m2; normal renal function (NRF) (no proteinuria and eGFR>75ml/min/1.73 m2); and Acute Kidney Disease (AKD) neither meeting criteria for CKD or NRF. AKI was confirmed within 7days by sCr increase or decrease of 0.3 mg/dl or 1.5x from the enrollment value. Pt outcomes: progression of AKI, need for RRT, hospitalization, mortality and renal functional recovery, were assessed at 7days and 1, 3 and 6 mos.

Results

3577pts were screened, 2101enrolled; 91%adults, 9%children. At enrollment, 9% were CKD and 66% AKD. At 7 days, 30% of pts fulfilled criteria for AKI: 67 from NRF (13%), AKD 470 (33%) and CKD 91 (46%). Overall mortality rate was 7.4% at 7 days and increased to 13% at 6 months. In comparison to NRF, AKD and CKD patients had higher mortality at 7 days and follow up, and the development of AKI trended for higher mortality in both AKD and CKD groups. Of 434 patients with 3 months sCr follow up, new onset CKD was encountered in 40(26%) of AKD and 54(33%) of AKI patients. Of patients dying from CKD and AKD groups, non-provision of dialysis occurred in 31 (11%).

Conclusion

Kidney dysfunction is common in CHC and is associated with adverse outcomes. POC tests can identify patients with AKD and CKD at increased risk for AKI, progression of CKD and mortality. Early implementation of targeted interventions may help improve outcomes.

Funding

  • Private Foundation Support